
Keywords: AECA; anti-endothelial cell antibodies; AD; autoimmune disease; APRIL; proliferation-inducing ligand; a-SMA; alfa smooth muscle actin; BAFF; factor B-cell activating factor; BAL; broncoalveolar lavage; CH; capillary hemangiomatosis; DAD; diffuse alveolar